BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
Interested parties may access a live audio webcast of the conference callvia the investor section of the BioMarin website, http://www.BMRN.com. Areplay of the call will be archived on the site for one week following thecall.
BioMarin develops and commercializes innovative biopharmaceuticals forserious diseases and medical conditions. The company's product portfoliocomprises three approved products and multiple clinical and preclinicalproduct candidates. Approved products include Naglazyme(R) (galsulfase) formucopolysaccharidosis VI (MPS VI), a product wholly developed andcommercialized by BioMarin; Aldurazyme(R) (laronidase) formucopolysaccharidosis I (MPS I), a product which BioMarin developed through a50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterindihydrochloride) Tablets, a product for the treatment of phenylketonuria(PKU), developed in partnership with Merck Serono, a division of Merck KGaA ofDarmstadt, Germany. Other product candidates include 6R-BH4 forcardiovascular indications, which is currently in Phase 2 clinical developmentfor the treatment of peripheral arterial disease and sickle cell disease, andPEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which iscurrently in Phase 1 clinical development for the treatment of PKU. Foradditional information, please visit http://www.BMRN.com. Information onBioMarin's website is not incorporated by reference into this press release.
BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks ofBioMarin Pharmaceutical Inc.Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. Contacts: Investors Media Eugenia Shen Susan Berg BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 506-6570 (415) 506-6594
SOURCE BioMarin Pharmaceutical Inc.
You May Also Like